This is the authors' abstract. We don't add key points for this paper.
In this cohort study, pricing data from January 2007 to June 2018 from SSR Health were used to determine how list prices, net prices, and discounts for the originator biologics changed with biosimilar competition.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
San-Juan-Rodriguez et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: